# Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement

> **NCT05391607** · PHASE4 · COMPLETED · sponsor: **Insel Gruppe AG, University Hospital Bern** · enrollment: 42 (actual)

## Conditions studied

- Blood Loss, Surgical
- Fluid Retention

## Interventions

- **DRUG:** Hyperoncotic Albumin 20%
- **DRUG:** Isooncotic Albumin 5%
- **DRUG:** Ringer's Lactate Crystalloid Solutions (control group)

## Key facts

- **NCT ID:** NCT05391607
- **Lead sponsor:** Insel Gruppe AG, University Hospital Bern
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-25
- **Primary completion:** 2023-03-30
- **Final completion:** 2023-04-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05391607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05391607, "Comparison Between Hyperoncotic and Isooncotic Albumin to Support Blood Loss Replacement". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05391607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*